Osel and partners launch Phase IIb FLIP-2 trial of Lactin-V
The trial builds on findings from the FLIP-1 Phase I study, which was conducted at the March of Dimes PRC.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance